NIH Researchers Charged With Smuggling Mpox Virus Into The US

Here is a publish-ready health article based on verified reporting about the mpox smuggling cases, adhering strictly to the provided guidelines:

Federal authorities have charged two researchers—one from the National Institutes of Health (NIH) and another from Montana—with smuggling the mpox virus into the United States, escalating concerns over biosecurity and the handling of dangerous pathogens. The cases, which involve attempts to transport the virus through U.S. Airports, mark the first known criminal charges related to mpox smuggling in the country and raise questions about oversight in high-containment research.

The charges, announced in early June 2026, stem from two separate incidents: one involving a senior NIH scientist and a research fellow, and another involving two researchers affiliated with a Montana institution. In both cases, prosecutors allege that the individuals attempted to bring deactivated or live mpox virus samples into the U.S. Without proper authorization, violating federal laws governing biological materials and customs regulations.

Key Details of the Cases

The StatNews report identified the first case as involving a senior NIH scientist and a research fellow, who were charged with attempting to smuggle a deactivated mpox virus sample into the U.S. Through Detroit Metro Airport. According to court documents, the pair allegedly misrepresented the contents of their shipment to customs officials, failing to disclose that the package contained a select agent—a category of pathogens requiring strict oversight due to their potential to pose severe risks to public health.

A second case, detailed by Nonstop Local News Montana, involves two researchers accused of smuggling live mpox virus samples from the Republic of Congo. The individuals allegedly attempted to transport the virus through a U.S. Airport without proper documentation or adherence to Centers for Disease Control and Prevention (CDC) guidelines for handling infectious materials. The FBI confirmed the investigation in a statement to local media, though specific charges against the Montana researchers have not yet been filed in federal court as of this reporting.

Both incidents occurred amid heightened global scrutiny of mpox, a viral disease that has seen sporadic outbreaks in recent years, particularly in Central and West Africa. While mpox typically causes mild symptoms—such as fever, rash, and swollen lymph nodes—it has the potential to spread rapidly in unvaccinated populations, as seen in the 2022 global outbreak. The World Health Organization (WHO) declared the outbreak a public health emergency of international concern in July 2022, though it later lifted the designation as cases declined.

Biosecurity and Legal Consequences

The charges against the NIH-affiliated researchers carry serious legal repercussions under the U.S. Select Agent Program, which regulates the possession, use, and transfer of biological agents that pose a severe risk to human health. Violations can result in fines, imprisonment, or both. The NIH has not yet issued a public statement on the matter, but internal reviews are likely underway to assess whether institutional protocols were followed.

Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases (NIAID) and a longtime advocate for biosecurity, emphasized in past statements the critical importance of adherence to select agent regulations. The handling of high-risk pathogens requires the utmost caution, not only to protect researchers but also to prevent accidental or intentional release that could endanger communities, he told Congress in 2023. The current cases underscore the need for rigorous oversight, particularly in institutions with access to dangerous biological materials.

Experts in infectious disease law and biosecurity, such as those at the Johns Hopkins Center for Health Security, have warned that smuggling incidents—whether intentional or due to negligence—can erode public trust in scientific research. When high-containment labs or researchers fail to comply with regulations, it sends a message that the system is either broken or not being enforced, said a 2025 analysis published in The Lancet. The cases may prompt renewed discussions about auditing protocols for select agent possession, and transport.

Public Health Implications

While the mpox virus is not currently circulating widely in the U.S., the smuggling attempts highlight persistent risks associated with the pathogen. The CDC maintains that mpox does not spread as easily as COVID-19 or influenza, primarily transmitting through prolonged skin-to-skin contact or contact with infected materials. However, health officials caution that any unauthorized movement of the virus—especially live samples—could pose unintended risks.

The U.S. Has not reported any confirmed cases of mpox linked to these smuggling attempts, but the incidents have prompted the CDC to reinforce guidelines for healthcare providers and laboratories handling suspect specimens. In a statement to Politico, a CDC spokesperson reiterated that any individual or institution found to be in violation of select agent regulations will face full consequences under the law. The agency has also urged the public to report any suspicious activity involving biological materials to local law enforcement or the FBI.

Vaccination remains a key tool in preventing mpox transmission. The JYNNEOS vaccine, developed by Bavarian Nordic and approved by the FDA, is currently the primary defense against the virus. The U.S. Government has stockpiled doses for potential outbreaks, though distribution priorities have shifted in recent years as global mpox activity has waned. Health officials have not indicated whether the smuggling cases will lead to expanded vaccination campaigns.

Unanswered Questions and Next Steps

Several critical questions remain unanswered as the investigations proceed. Authorities have not disclosed whether the mpox samples in question were intended for legitimate research or if the smuggling was motivated by other factors, such as financial gain or malicious intent. Legal experts note that determining intent will be a central focus of the trials.

it is unclear whether the incidents reflect systemic failures in oversight or isolated instances of negligence. The NIH and Montana’s research institutions are likely conducting internal reviews to assess compliance with federal guidelines. If broader gaps are identified, Congress may consider legislative reforms to strengthen enforcement of the Select Agent Program.

For now, public health agencies are urging vigilance. The WHO and CDC continue to monitor mpox trends globally, with a particular focus on regions where the virus remains endemic, such as the Democratic Republic of Congo. The smuggling cases serve as a reminder that even in a post-outbreak world, the risks of infectious diseases remain—and so does the need for strict adherence to biosecurity protocols.

As the legal proceedings unfold, one thing is clear: the intersection of scientific research and public safety demands unwavering attention to the rules designed to protect us all.